People using assistive technology may not be able to fully access information in these files. For additional assistance, please contact us.
Archived: The systematic review on which this report is based has been updated. Findings from this report may be used for research purposes, but should not be considered current.
This report is from AHRQ's series on Future Research Needs Projects.
This future research needs (FRN) report is based on an Agency for Healthcare Research and Quality (AHRQ) comparative effectiveness review (CER) titled "First- and Second-Generation Antipsychotics for Children and Young Adults." The purpose of the CER was to review and synthesize the evidence regarding the benefits and harms of first- and second-generation antipsychotics (FGAs and SGAs) for the treatment of various psychiatric and behavioral conditions in individuals 24 years of age or younger.